These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 11173124

  • 1. Therapeutic targets in radiotherapy.
    Brown JM.
    Int J Radiat Oncol Biol Phys; 2001 Feb 01; 49(2):319-26. PubMed ID: 11173124
    [Abstract] [Full Text] [Related]

  • 2. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.
    Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ.
    Prostate; 2005 Jan 01; 62(1):69-82. PubMed ID: 15389805
    [Abstract] [Full Text] [Related]

  • 3. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
    Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ.
    Cancer Res; 2001 Mar 01; 61(5):2289-93. PubMed ID: 11280800
    [Abstract] [Full Text] [Related]

  • 4. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
    Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ.
    Radiat Res; 2000 Aug 01; 154(2):125-32. PubMed ID: 10931682
    [Abstract] [Full Text] [Related]

  • 5. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 6. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM, Lau N, Guha A.
    Oncogene; 1999 Dec 09; 18(52):7514-26. PubMed ID: 10602510
    [Abstract] [Full Text] [Related]

  • 7. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
    Brown JM, Lemmon MJ.
    Int J Radiat Oncol Biol Phys; 1991 Mar 09; 20(3):457-61. PubMed ID: 1995531
    [Abstract] [Full Text] [Related]

  • 8. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
    Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG.
    Cancer Res; 1996 Apr 15; 56(8):1727-30. PubMed ID: 8620483
    [Abstract] [Full Text] [Related]

  • 9. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS.
    Leukemia; 2003 Feb 15; 17(2):451-7. PubMed ID: 12592346
    [Abstract] [Full Text] [Related]

  • 10. Farnesyltransferase inhibitors as radiation sensitizers.
    McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ.
    Semin Radiat Oncol; 2002 Jul 15; 12(3 Suppl 2):27-32. PubMed ID: 12174342
    [Abstract] [Full Text] [Related]

  • 11. Farnesyltransferase inhibitors as radiation sensitizers.
    Brunner TB, Gupta AK, Shi Y, Hahn SM, Muschel RJ, McKenna WG, Bernhard EJ.
    Int J Radiat Biol; 2003 Jul 15; 79(7):569-76. PubMed ID: 14530152
    [Abstract] [Full Text] [Related]

  • 12. The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities.
    Feldkamp MM, Lau N, Guha A.
    Ann N Y Acad Sci; 1999 Jul 15; 886():257-60. PubMed ID: 10667233
    [No Abstract] [Full Text] [Related]

  • 13. Signaling inhibition with radiation in colorectal cancer: clinical trials.
    McKenna WG, Muschel RJ, Gupta A, Hahn S, Bernhard EJ.
    Semin Oncol; 2003 Jun 15; 30(3 Suppl 6):56-67. PubMed ID: 12802796
    [Abstract] [Full Text] [Related]

  • 14. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K, Nagasu T.
    Gan To Kagaku Ryoho; 1997 Jan 15; 24(2):145-55. PubMed ID: 9030225
    [Abstract] [Full Text] [Related]

  • 15. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM, Lemmon MJ.
    Radiother Oncol; 1991 Jan 15; 20 Suppl 1():151-6. PubMed ID: 2020764
    [Abstract] [Full Text] [Related]

  • 16. Inhibitors of the ras oncogene as therapeutic targets.
    Ghobrial IM, Adjei AA.
    Hematol Oncol Clin North Am; 2002 Oct 15; 16(5):1065-88. PubMed ID: 12512383
    [Abstract] [Full Text] [Related]

  • 17. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
    Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ, Bentzen SM, Okunieff P, Coleman CN, Dicker AP.
    J Natl Cancer Inst; 2013 Jan 02; 105(1):11-24. PubMed ID: 23231975
    [Abstract] [Full Text] [Related]

  • 18. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 19. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
    Cox AD.
    Drugs; 2001 Dec 27; 61(6):723-32. PubMed ID: 11398905
    [Abstract] [Full Text] [Related]

  • 20. RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
    Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E, Favre G.
    Oncogene; 2002 Sep 05; 21(39):5998-6006. PubMed ID: 12203112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.